Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) presented at this year’s virtual ASCO.
Adrian Kilcoyne, MD on Phase III ADAURA Trial For TAGRISSO @AstraZeneca #ASCO2020 #ASCO
